antigen

(redirected from tumor antigen)
Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to tumor antigen: Cancer Antigen

an·ti·gen

 (ăn′tĭ-jən) also an·ti·gene (-jēn′)
n.
A molecule that is capable of binding to an antibody or to an antigen receptor on a T cell, especially one that induces an immune response. An antigen is usually a foreign substance, such as a toxin or a component of a virus, bacterium, or parasite.

an′ti·gen′ic (-jĕn′ĭk) adj.
an′ti·gen′i·cal·ly adv.
an′ti·ge·nic′i·ty (-jə-nĭs′ĭ-tē) n.

antigen

(ˈæntɪdʒən; -ˌdʒɛn) or

antigene

n
(Biochemistry) a substance that stimulates the production of antibodies
[C20: from anti(body) + -gen]
ˌantiˈgenic adj
ˌantiˈgenically adv

an•ti•gen

(ˈæn tɪ dʒən, -ˌdʒɛn)

n.
1. any substance that can stimulate the production of antibodies and combine specifically with them.
2. any commercial substance that, when injected or absorbed into animal tissues, stimulates the production of antibodies.
3. antigens of a particular type collectively.
[1905–10; anti (body) + -gen]
an`ti•gen′ic, adj.
an`ti•gen′i•cal•ly, adv.
an`ti•ge•nic′i•ty (-dʒəˈnɪs ɪ ti) n.

an·ti·gen

(ăn′tĭ-jən)
A substance that stimulates the production of an antibody when introduced into the body. Antigens include toxins, bacteria, viruses, and other foreign substances. See Note at blood type.

antigen

A molecule recognized as foreign by the body’s immune system, causing the release of antibodies.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.antigen - any substance (as a toxin or enzyme) that stimulates an immune response in the body (especially the production of antibodies)
substance - a particular kind or species of matter with uniform properties; "shigella is one of the most toxic substances known to man"
immunizing agent, immunogen - any substance or organism that provokes an immune response (produces immunity) when introduced into the body
immunology - the branch of medical science that studies the body's immune system
agglutinogen - any substance that acts as an antigen to cause agglutinin production
fetoprotein, foetoprotein - any of several antigens that occur naturally in the fetus and sometimes in adults with cancer
anatoxin, toxoid - a bacterial toxin that has been weakened until it is no longer toxic but is strong enough to induce the formation of antibodies and immunity to the specific disease caused by the toxin; "diphtheria toxoid"
antigenic determinant, epitope, determinant - the site on the surface of an antigen molecule to which an antibody attaches itself
Rh, Rh factor, rhesus factor - a blood group antigen possessed by Rh-positive people; if an Rh-negative person receives a blood transfusion from an Rh-positive person it can result in hemolysis and anemia
Translations
antigen
antigeeni
antigén
antígeno
antigen
antigen

antigen

[ˈæntɪdʒən] Nantígeno m

antigen

[ˈæntɪdʒən] nantigène manti-hero antihero [ˈæntihɪərəʊ] nantihéros m

antigen

nAntigen nt

antigen

[ˈæntɪdʒən] nantigene m

an·ti·gen

n. antígeno, sustancia tóxica que estimula la formación de anticuerpos;
carcinoembriogenic ______ carcinoembriogénico.

antigen

n antígeno; carcinoembryonic — antígeno carcinoembrionario; prostate-specific — (PSA) antígeno prostático específico (APE)
References in periodicals archive ?
Global Markets Direct's, 'Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016', provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
The density of tumor antigen expression can also affect the selection of CART-cell targets [22].
By targeting tumor antigen presentation, MEDI9197 adds a unique mechanism of immune activation to our growing portfolio and supports our strategy of maximizing anti-tumor immunity through scientifically rational combinations.
Bladder tumor antigen test," "BTA stat," "urine cytology," "cytology," "diagnosis," "bladder cancer," "study" and "trial" were the key words.
TEHRAN (FNA)- Iranian researchers from Tarbiat Modarres University in association with their colleagues from Cellular and Molecular Research Institute of Shahid Beheshti University succeeded in the primary production of cancer breast tumor antigen carriers.
The researchers described the use of T-cells that were taken from a donor, programmed in the lab to recognize the Wilm's Tumor Antigen 1 (WT1) and kill leukemia cells, grown in large numbers, and then infused into patients to promote anti-leukemic activity.
In the UCLA clinical trial, peripheral blood mononuclear cells (PBMCs) collected from melanoma patients are retrovirally-transduced in vitro utilizing the RetroNectin method with a gene encoding T-cell receptor (TCR) which specifically recognizes tumor antigen MART-1 expressing on melanoma cells.
8) Study Evaluates Immune Response to Telomerase Tumor Antigen as Possible Vaccine.
This discovery provides for the potential development of a cancer vaccine directed at the HER-2 antigen, known to be an important tumor antigen in multiple cancer indications.
Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
We concluded that CA 15-3 was the best tumor antigen for use as a diagnostic aid and monitoring agent.
Tumor markers used in this study were the nuclear matrix protein (Matritech NMP-22) and the bladder tumor antigen (Bard BTA), which are commercially available, and the telomerase assay (TRAP) which is currently under investigation.